Novartis AG has synthesized heteroaryl aminopropanol derivatives acting as leukotriene A4 hydrolase (LTA4H; LTA4) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease (COPD), psoriasis, sepsis, periodontal and autoimmune disease, cardiovascular and inflammatory disorders, among others.
Medshine Discovery Inc. and Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. have disclosed bicyclic substituted aromatic carboxylic acid compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of Parkinson's disease.
Bayer AG has described phosphorus derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Boehringer Ingelheim Pharma GmbH & Co. KG has divulged imidazo[4,5-d]pyridazinonyl derivatives acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of cough, fibrosis, respiratory tract inflammation and idiopathic pulmonary fibrosis.
Qingdao Ruiji Medical Technology Co. Ltd. has identified benzofuran derivatives acting as farnesoid X receptor (FXR) agonists reported to be useful for the treatment of cancer, inflammation, metabolic, cardiovascular, liver, inflammatory bowel and renal diseases.
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others.
Tuojie Biotech (Shanghai) Co. Ltd. has disclosed boric acid derivatives acting as β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infections.
Orion Corp. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, musculoskeletal and neuropathic pain.
Neuropn Therapeutics LLC has divulged piperidine urea derivatives as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of Parkinson's disease, pain, inflammation and neurodegeneration.
RSS